PARP inhibitor is named as a drug or biological intervention in 5 clinical trials in our China trial register, 4 of which are recruiting. Lead sponsors include Peking Union Medical College (1), Fudan University (1) and The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1). Registered phases: Phase 2 and Observational. Conditions studied include Salivary Gland Carcinoma; Precision Therapy; Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| Breast Cancer | 1 |
| Neoadjuvant Therapy | 1 |
| High Risk Prostate Cancer | 1 |
| Locally Advanced Prostate Cancer | 1 |
| Intense Endocrine Therapy | 1 |
| Ovarian Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Primary Peritoneal Carcinoma | 1 |
| Breast | 1 |
| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College | 1 |
| Fudan University | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| Shanghai Gynecologic Oncology Group | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Register | PARP inhibitor trials |
|---|---|
| Clinical trials in China | 5 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PARP inhibitor works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PARP inhibitor (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.